Skip to main navigation Skip to search Skip to main content

Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signaling

Erika Heninger, David Kosoff, Tamara S. Rodems, Nan Sethakorn, Anupama Singh, Harshitha Gungurthi, Kristin N. Carlson, Bing Yang, Cole Gilsdorf, Cheri A. Pasch, Dustin A. Deming, Leigh Ellis, David J. Beebe, David F. Jarrard, Joshua M. Lang*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Prostate Cancer (PC) is a disease with remarkable tumor heterogeneity that often manifests in significant intra-patient variability with regards to clinical outcomes and treatment response. Commonly available PC cell lines do not accurately reflect the complexity of this disease and there is critical need for development of new models to recapitulate the intricate hierarchy of tumor pathogenesis. In current study, we established ex vivo primary patient-derived cancer organoid (PDCO) cultures from prostatectomy specimens of patients with locally advanced PC. We then performed a comprehensive multi-parameter characterization of the cellular composition utilizing a novel approach for live-cell staining and direct imaging in the integrated microfluidic Stacks device. Using orthogonal flow cytometry analysis, we demonstrate that primary PDCOs maintain distinct subsets of epithelial cells throughout culture and that these cells conserve expression of androgen receptor (AR)-related elements. Furthermore, to confirm the tumor-origin of the PDCOs we have analyzed the expression of PC-associated epigenetic biomarkers including promoter methylation of the GSTP1, RASSF1 and APC and RARb genes by employing a novel microfluidic rare-event screening protocol. These results demonstrate that this ex vivo PDCO model recapitulates the complexity of the epithelial tumor microenvironment of multifocal PC using orthogonal analyses. Furthermore, we propose to leverage the Stacks microfluidic device as a high-throughput, translational platform to interrogate phenotypic and molecular endpoints with the capacity to incorporate a complex tumor microenvironment.

Original languageEnglish
Article number135
JournalMedical Oncology
Volume38
Issue number11
DOIs
StatePublished - Nov 2021

Keywords

  • Epigenetic biomarker
  • Microfluidics
  • PDCO
  • Primary culture
  • Prostate cancer

Cite this